Search research articles
Contact Us
Filters
Showing results (11-20 of 26) with videos related to
Page
of 3
Sort By:
Journal of Hematology & Oncology
|
April 19, 2015
Insulin like growth factor binding protein 7 (IGFBP7) expression is linked to poor prognosis but may protect from bone disease in multiple myeloma
Arnold Bolomsky, Dirk Hose, Martin Schreder, et al.
Journal of Applied Genetics
|
October 16, 2025
Carfilzomib resistance in multiple myeloma: A comparative metabolomic analysis
Krzysztof Żyłka, Magdalena Łuczak, Magdalena Kostrzewska-Poczekaj, et al.
Leukemia & Lymphoma
|
June 3, 2017
Molecular mechanisms, current management and next generation therapy in myeloma bone disease
Roy Heusschen, Joséphine Muller, Elodie Duray, et al.
British Journal of Haematology
|
April 10, 2013
High expression of cereblon (CRBN) is associated with improved clinical response in patients with multiple myeloma treated with lenalidomide and dexamethasone
Daniel Heintel, Alberto Rocci, Heinz Ludwig, et al.
Leukemia
|
October 29, 2023
CTPS1 is a novel therapeutic target in multiple myeloma which synergizes with inhibition of CHEK1, ATR or WEE1
Christina Pfeiffer, Alexander M Grandits, Hélène Asnagli, et al.
American Journal of Hematology
|
January 5, 2017
IKAROS expression in distinct bone marrow cell populations as a candidate biomarker for outcome with lenalidomide-dexamethasone therapy in multiple myeloma
Arnold Bolomsky, Wolfgang Hübl, Stefano Spada, et al.
Biorxiv : the Preprint Server for Biology
|
January 16, 2026
Phosphorylation Protects Oncogenic RAS from LZTR1-Mediated Degradation
Lin Zhang, Arnold Bolomsky, Omar S Al-Odat, et al.
British Journal of Haematology
|
April 2, 2020
The anti-mitotic agents PTC-028 and PTC596 display potent activity in pre-clinical models of multiple myeloma but challenge the role of BMI-1 as an essential tumour gene
Arnold Bolomsky, Joséphine Muller, Kathrin Stangelberger, et al.
Haematologica
|
May 12, 2018
Maternal embryonic leucine zipper kinase inhibitor OTSSP167 has preclinical activity in multiple myeloma bone disease
Joséphine Muller, Arnold Bolomsky, Sophie Dubois, et al.
British Journal of Haematology
|
June 29, 2011
Lenalidomide downregulates the cell survival factor, interferon regulatory factor-4, providing a potential mechanistic link for predicting response
Antonia Lopez-Girona, Daniel Heintel, Ling-Hua Zhang, et al.
Page
of 3
Search research articles
Search
Showing results (11-20 of 26) with videos related to
Sort By:
Page
of 3
Journal of Hematology & Oncology
|
April 19, 2015
Insulin like growth factor binding protein 7 (IGFBP7) expression is linked to poor prognosis but may protect from bone disease in multiple myeloma
Arnold Bolomsky, Dirk Hose, Martin Schreder, et al.
Journal of Applied Genetics
|
October 16, 2025
Carfilzomib resistance in multiple myeloma: A comparative metabolomic analysis
Krzysztof Żyłka, Magdalena Łuczak, Magdalena Kostrzewska-Poczekaj, et al.
Leukemia & Lymphoma
|
June 3, 2017
Molecular mechanisms, current management and next generation therapy in myeloma bone disease
Roy Heusschen, Joséphine Muller, Elodie Duray, et al.
British Journal of Haematology
|
April 10, 2013
High expression of cereblon (CRBN) is associated with improved clinical response in patients with multiple myeloma treated with lenalidomide and dexamethasone
Daniel Heintel, Alberto Rocci, Heinz Ludwig, et al.
Leukemia
|
October 29, 2023
CTPS1 is a novel therapeutic target in multiple myeloma which synergizes with inhibition of CHEK1, ATR or WEE1
Christina Pfeiffer, Alexander M Grandits, Hélène Asnagli, et al.
American Journal of Hematology
|
January 5, 2017
IKAROS expression in distinct bone marrow cell populations as a candidate biomarker for outcome with lenalidomide-dexamethasone therapy in multiple myeloma
Arnold Bolomsky, Wolfgang Hübl, Stefano Spada, et al.
Biorxiv : the Preprint Server for Biology
|
January 16, 2026
Phosphorylation Protects Oncogenic RAS from LZTR1-Mediated Degradation
Lin Zhang, Arnold Bolomsky, Omar S Al-Odat, et al.
British Journal of Haematology
|
April 2, 2020
The anti-mitotic agents PTC-028 and PTC596 display potent activity in pre-clinical models of multiple myeloma but challenge the role of BMI-1 as an essential tumour gene
Arnold Bolomsky, Joséphine Muller, Kathrin Stangelberger, et al.
Haematologica
|
May 12, 2018
Maternal embryonic leucine zipper kinase inhibitor OTSSP167 has preclinical activity in multiple myeloma bone disease
Joséphine Muller, Arnold Bolomsky, Sophie Dubois, et al.
British Journal of Haematology
|
June 29, 2011
Lenalidomide downregulates the cell survival factor, interferon regulatory factor-4, providing a potential mechanistic link for predicting response
Antonia Lopez-Girona, Daniel Heintel, Ling-Hua Zhang, et al.
Page
of 3